SXI Life Sciences
7.772,36
PKT
-3,32
PKT
-0,04
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 19.01.23 | Roche Sell | Deutsche Bank AG | |
| 09.01.23 | Roche Neutral | UBS AG | |
| 09.01.23 | Novartis Neutral | UBS AG | |
| 06.01.23 | Roche Outperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underweight | Morgan Stanley | |
| 05.01.23 | Novartis Buy | Jefferies & Company Inc. | |
| 05.01.23 | Roche Hold | Jefferies & Company Inc. | |
| 03.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 23.12.22 | Novartis Underweight | Barclays Capital | |
| 23.12.22 | Roche Overweight | Barclays Capital | |
| 14.12.22 | Novartis Neutral | UBS AG | |
| 14.12.22 | Roche Neutral | UBS AG | |
| 12.12.22 | Novartis Buy | Jefferies & Company Inc. | |
| 09.12.22 | Novartis Sell | Deutsche Bank AG | |
| 08.12.22 | Novartis Market-Perform | Bernstein Research | |
| 08.12.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.12.22 | Novartis Sell | Deutsche Bank AG | |
| 06.12.22 | Novartis Neutral | UBS AG | |
| 02.12.22 | Roche Hold | Deutsche Bank AG | |
| 22.11.22 | Novartis Sell | Deutsche Bank AG | |
| 15.11.22 | Roche Hold | Deutsche Bank AG | |
| 14.11.22 | Roche Outperform | Credit Suisse Group | |
| 14.11.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 14.11.22 | Roche Overweight | Barclays Capital | |
| 14.11.22 | Roche Buy | Jefferies & Company Inc. | |
| 14.11.22 | Roche Neutral | UBS AG | |
| 14.11.22 | Roche Outperform | Bernstein Research | |
| 01.11.22 | Roche Hold | Deutsche Bank AG | |
| 27.10.22 | Novartis Sell | Deutsche Bank AG | |
| 26.10.22 | Novartis Market-Perform | Bernstein Research | |
| 26.10.22 | Novartis Underperform | Credit Suisse Group | |
| 26.10.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 26.10.22 | Novartis Underweight | Barclays Capital | |
| 25.10.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.10.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 25.10.22 | Novartis Sell | Deutsche Bank AG | |
| 25.10.22 | Novartis Neutral | UBS AG |